Novartis' Zia On Momentum Amid Policy Strain In India
Executive Summary
As Novartis continues to battle Glivec-related pain in India, its country president Jawed Zia tells Scrip that the Swiss multinational has been hit "particularly hard" after the government withdrew customs duty exemptions on more than 70 drugs including imatinib mesylate earlier this year.